* Personal Statement
The advent of small molecule peptide imaging and therapy (theranostics) is changing the face of oncology diagnosis, prognosis and treatment.
This has had a dramatic impact in prostate cancer, with a paradigm shift in clinical practice. At the forefront of this shift in clinical practice,
I have both commenced and contributed to multiple imaging and therapy trials in prostate cancer using PSMA PET and PSMA targeted therapy between 2014 and 2022. I have lead and contributed to national prospective trials in PSMA imaging and therapy of prostate cancer in Australia which have been practice changing. Personally, this has involved being Principal Investigator on multiple prospective imaging (PROPS, PRIMARY, PRIMARY2) and therapy (LUPIN, AcTION, ENZAp) trials in addition to being a member on various steering committees and supportive of many more trials (Upfront PSMA, LuPARP, PRINCE, EVOLUTION). It has been and continues to be a wonderful time to be involved in clinical theranostics research and actively enable positive change.
